A phase 2, multicenter, randomized, double-blind, placebo controlled parallel-group study evaluating the efficacy and safety of golimumab administered subcutaneously in symptomatic subjects with severe, persistent asthma.

Trial Profile

A phase 2, multicenter, randomized, double-blind, placebo controlled parallel-group study evaluating the efficacy and safety of golimumab administered subcutaneously in symptomatic subjects with severe, persistent asthma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Golimumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Centocor
  • Most Recent Events

    • 24 Jul 2008 Status changed from initiated to withdrawn prior to recruitment (information from ClinicalTrials.gov).
    • 02 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top